
Establishing a new treatment for depression using VR
BiPSEE is currently working with research institutions to conduct clinical research and is aiming for medical device approval for this product, BiPSEE is currently collaborating with research institutions and conducting clinical studies with the aim of obtaining medical device approval for this development product.
Under the terms of the agreement, Meiji Seika Pharma will support BiPSEE's research and development activities to obtain regulatory approval for the product.
Depression, which is rapidly increasing in the recent stressful society, has become a major social issue as the biggest cause of long-term absence from work, unemployment, and suicide. In addition, the number of people suffering from depression and suicides has increased sharply again due to behavioral restrictions such as refraining from going out of the house and economic uncertainty caused by the prolonged Corona disaster. Meiji Seika Pharma has accumulated more than 30 years of experience in the anxiety and depression area through the provision of ethical drugs. By leveraging this expertise, Meiji Seika Pharma will contribute to the next generation of psychiatric care through this business alliance agreement.
BiPSEE and Meiji Seika Pharma will contribute to mental and physical health by creating and providing VR digital solutions to each and every patient.

About BiPSEE
We are working to establish a new treatment method that applies the advanced visual simulation of VR and is based on approaches such as third-generation cognitive-behavioral therapy, which distances the patient from the emotions and thoughts behind "anti-numeric thinking," a factor that causes depressed mood to persist. We are currently conducting clinical research with research institutions and aiming for medical device approval. For more information, please refer to the following website.
| name of company | BiPSEE Corporation |
| Establishment | Established July 2017 |
| Location | 1-3-18 Hiroo, Shibuya-ku, Tokyo |
| representative | Masayo Matsumura |
| uniform resouce locator | https://bipsee.co.jp/ |

About Meiji Seika Pharma
In the area of the central nervous system, Meiji Seika Pharma was the first to launch a new antidepressant (SSRI), which is now the mainstream treatment in Japan since the launch of an anti-anxiety drug in 1989, and has accumulated more than 30 years of experience in the anxiety and depression area by supplying high-quality generic drugs as a new drug manufacturer. We have accumulated more than 30 years of experience in the field of anxiety and depression.
For details, please refer to the following website.
https://www.meiji-seika-pharma.co.jp/









